A metaanalysis including 17 NSCLC EGFR tyrosine kinase inhibitor clinical studies with 1008 patient tumors and 8 metastatic colorectal cancer (mCRC) studies of anti-EGFR monoclonal antibody-based therapies in 817 mCRC patients found that KRAS mutations were significantly associated with absence of response to EGFR-targeted therapies for these cancers [47]. This evidence concerns the gene EGFR and cancer.